Immunoprecise Antibodies Ltd Stock Other OTC
Stocks
CA87588T1030
Pharmaceuticals
| Market Cap | 89.52M 63.9M 55.72M 52.62M 47.78M 6.13B 89.89M 630M 243M 3.12B 240M 235M 10.03B | P/E 2027 * |
-4.56x | P/E 2028 * | -6.8x |
|---|---|---|---|---|---|
| Enterprise Value | 89.52M 63.9M 55.72M 52.62M 47.78M 6.13B 89.89M 630M 243M 3.12B 240M 235M 10.03B | EV / Sales 2027 * |
5.07x | EV / Sales 2028 * | 3.8x |
| Free-Float |
90.86% | Yield 2027 * |
-
| Yield 2028 * | - |
Last Transcript: Immunoprecise Antibodies Ltd
| 1 day | -6.29% |
| Manager | Title | Age | Since |
|---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 21/02/2018 |
Richard Areglado
DFI | Director of Finance/CFO | 62 | 20/10/2025 |
Hyfte Van
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Jennifer Bath
BRD | Director/Board Member | - | 24/05/2018 |
Dirk Witters
CHM | Chairman | - | - |
Jonathan Lieber
BRD | Director/Board Member | 56 | 07/07/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.29% | -23.22% | - | - | 63.9M | |
| -0.58% | +0.43% | +32.58% | -6.20% | 78.37B | |
| -2.55% | +6.99% | +510.30% | +44.31% | 61.5B | |
| -1.11% | +5.08% | -11.48% | -33.39% | 59.78B | |
| +0.14% | -1.20% | -11.21% | +24.73% | 46.53B | |
| -0.24% | +1.22% | +2.36% | +154.40% | 45.5B | |
| -1.62% | -0.76% | +51.23% | -16.04% | 31.84B | |
| -1.81% | +3.16% | +44.82% | +106.78% | 25.4B | |
| +0.47% | +3.26% | +4.94% | +144.25% | 21.43B | |
| +0.27% | +1.96% | +59.19% | +106.18% | 15.77B | |
| Average | -1.33% | +2.20% | +75.86% | +58.34% | 42.9B | |
| Weighted average by Cap. | -0.92% | +2.35% | +94.90% | +39.85% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 17.67M 12.61M 11M 10.38M 9.43M 1.21B 17.74M 124M 48M 615M 47.38M 46.32M 1.98B | 23.55M 16.81M 14.66M 13.84M 12.57M 1.61B 23.65M 166M 63.98M 820M 63.14M 61.74M 2.64B |
| Net income | -19.59M -13.99M -12.2M -11.52M -10.46M -1.34B -19.67M -138M -53.23M -682M -52.54M -51.37M -2.2B | -13.71M -9.78M -8.53M -8.06M -7.32M -939M -13.76M -96.49M -37.24M -477M -36.75M -35.94M -1.54B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
